FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The U.S. Food and Drug Administration has declined to approve ivonescimab, a PD-1xVEGF bispecific antibody developed by Summit Therapeutics and Akeso, for non-small cell lung cancer. The rejection follows the drug's failure to meet a key survival goal in a pivotal trial. The decision blocks the U.S. introduction of this China-originated class and represents a setback for Summit's commercial plans and China's biotech sector ambitions. The FDA has published its rejection letter outlining multiple issues with the application.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA declined to approve Summit Therapeutics and Akeso's ivonescimab for non-small cell lung cancer after the trial missed a key survival goal.
- ✓ Ivonescimab is a PD-1xVEGF bispecific antibody that originated in China.
- ✓ The FDA published a rejection letter citing several issues with the biologics license application.
What changed
The FDA has formally rejected Summit's biologics license application for ivonescimab after the pivotal lung cancer trial missed its key survival goal.
Live updates
-
FDA rejects Summit and Akeso's ivonescimab for lung cancer
The U.S. Food and Drug Administration has declined to approve ivonescimab, a PD-1xVEGF bispecific antibody developed by Summit Therapeutics and Akeso, for non-small cell lung cancer. The rejection follows the drug's failure to meet a key survival goal in a pivotal trial. The decision blocks the U.S. introduction of this China-originated class and represents a setback for Summit's commercial plans and China's biotech sector ambitions. The FDA has published its rejection letter outlining multiple issues with the application.
Why it matters
Ivonescimab was viewed as a leading candidate in the much-hyped PD-1xVEGF bispecific category, which combines immune checkpoint inhibition with vascular endothelial growth factor blockade. Summit had sought approval for a narrow lung cancer setting, but the trial's missed survival endpoint removed the regulatory path forward. The rejection arrives as Chinese-originated drugs face heightened scrutiny in U.S. markets and as Summit works to establish a commercial presence in the United States.
What is confirmed
- The FDA declined to approve Summit Therapeutics and Akeso's ivonescimab for non-small cell lung cancer after the trial missed a key survival goal.
- Ivonescimab is a PD-1xVEGF bispecific antibody that originated in China.
- The FDA published a rejection letter citing several issues with the biologics license application.
Still unconfirmed
- Summit may pursue additional clinical data or a resubmission for ivonescimab in the United States.
What to watch next
- Summit's response to the FDA rejection letter and any plans for further trials or resubmission
- Regulatory progress for ivonescimab in markets outside the United States
- Impact on Summit's valuation and partnership arrangements with Akeso
confidence 95%Sources used for this update (9)
- Fierce Pharma — FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
- Reuters — US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
- Yahoo Finance — Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Bloomberg.com — US FDA Rejects Summit’s China-Originated Lung Cancer Drug
- Endpoints News — FDA rejects Summit, Akeso’s ivonescimab in narrow lung cancer setting
- STAT — FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
- Financial Times — FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
- The New York Times — F.D.A. Rejects Closely Watched Lung Cancer Drug From China
- finance.yahoo.com — FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community